On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.

On the news front, the company announced that its inhaled sGC activator Mosliciguat achieved positive results in the Phocus study evaluating the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data validated the drug's efficacy, offering a potential breakthrough for a condition that has long lacked effective treatment options. Additionally, the company disclosed the ongoing Phrontier Phase III trial, marking a significant step forward in Mosliciguat's clinical development and reinforcing its potential therapeutic position in this rare disease indication.

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on inflammation and immunology. Its core pipeline also includes brepocitinib, currently under FDA review, and IMVT-1402, a fully human monoclonal antibody targeting the neonatal Fc receptor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)